Bernard Salick, who established Salick Health Care which was acquired byZeneca (Marketletters passim), is looking to raise around $300 million to enable him to compete directly with Zeneca's kidney and cancer clinics, reports the Financial Times.
Dr Salick and Zeneca parted company on bad terms after Mr Salick refused to accept Zeneca's offer of the post of chairman emeritus, in place of chief executive of Salick Health Care.
Bentley Health Care is Dr Salick's new venture which will consist of cancer and AIDS/HIV clinics. Dr Salick is understood to be investing $10-$20 million of his own funds into the project. Initially, he will set up in the New York area, which is being targeted by Zeneca. He also intends to move into California and Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze